Your browser is no longer supported. Please, upgrade your browser.
GSK GlaxoSmithKline plc daily Stock Chart
GlaxoSmithKline plc
Index- P/E125.86 EPS (ttm)0.34 Insider Own0.20% Shs Outstand2.63B Perf Week5.81%
Market Cap113.66B Forward P/E16.51 EPS next Y2.61 Insider Trans0.00% Shs Float2.43B Perf Month1.79%
Income841.20M PEG209.77 EPS next Q0.59 Inst Own8.90% Short Float0.23% Perf Quarter6.74%
Sales33.55B P/S3.39 EPS this Y204.10% Inst Trans-2.52% Short Ratio1.56 Perf Half Y11.85%
Book/sh1.58 P/B27.32 EPS next Y13.36% ROA1.10% Target Price47.00 Perf Year9.76%
Cash/sh2.33 P/C18.52 EPS next 5Y0.60% ROE12.20% 52W Range35.12 - 43.34 Perf YTD11.85%
Dividend2.22 P/FCF- EPS past 5Y40.20% ROI41.40% 52W High-0.39% Beta0.80
Dividend %5.14% Quick Ratio0.80 Sales past 5Y-3.40% Gross Margin66.40% 52W Low22.91% ATR0.85
Employees101192 Current Ratio1.10 Sales Q/Q10.80% Oper. Margin7.50% RSI (14)59.02 Volatility1.69% 1.49%
OptionableYes Debt/Eq6.05 EPS Q/Q-96.60% Profit Margin2.50% Rel Volume0.89 Prev Close43.34
ShortableYes LT Debt/Eq5.61 EarningsJul 27 Payout629.40% Avg Volume3.56M Price43.17
Recom2.00 SMA203.86% SMA502.71% SMA2008.88% Volume3,168,838 Change-0.39%
Mar-30-16Upgrade Citigroup Neutral → Buy
Feb-26-16Initiated Cantor Fitzgerald Hold
Dec-09-15Upgrade BofA/Merrill Neutral → Buy
Dec-07-15Reiterated Argus Buy $52 → $48
Oct-20-15Upgrade Credit Suisse Underperform → Neutral
Sep-15-15Upgrade Exane BNP Paribas Underperform → Neutral
Sep-08-15Upgrade BofA/Merrill Underperform → Neutral
Jun-26-15Upgrade Liberum Sell → Hold
Jun-04-15Downgrade Morgan Stanley Overweight → Equal-Weight
May-20-15Resumed Citigroup Neutral
Apr-15-15Initiated Societe Generale Sell
Feb-19-15Reiterated Argus Buy $55 → $52
Aug-08-14Reiterated Argus Buy $65 → $55
Apr-23-14Upgrade Argus Hold → Buy
May-28-13Upgrade Deutsche Bank Hold → Buy
Jan-11-11Upgrade Jefferies Hold → Buy
Jun-02-10Upgrade Jefferies Hold → Buy
Feb-16-10Upgrade JP Morgan Underweight → Neutral $26
Jan-13-10Downgrade Credit Suisse Outperform → Underperform
Nov-24-09Initiated Leerink Swann Mkt Perform
Jul-01-16 10:00AM  European Stocks: What's Your Pain Tolerance?
08:19AM  Better Buy: GlaxoSmithKline plc vs. Merck at Motley Fool
12:27AM  GSK's Strategy for Growth in Asia
Jun-30-16 01:49PM  New partnership looks to improve lives of children living with HIV at
05:00AM  Why Drug Companies Want to Sell Vaccines to Pregnant Women at Bloomberg
05:00AM  Why Drug Companies Want to Sell Vaccines to Pregnant Women
Jun-29-16 09:07AM  Why Market Share for Novo Nordisks Tresiba Is Set to Grow
Jun-28-16 06:30PM  Which Biotechnology Companies Could Benefit from Brexit?
01:28PM  New Stock Research Reports for June 28, 2016
11:06AM  Mylans Key Developments and Big Plans: What You Should Know
09:27AM  Shire and Glaxo Offer Prescription to London's Woes
Jun-27-16 11:45PM  Regulus Therapeutics Inc. Clinical Hold: Should Investors Be Yellow-Bellied? at Motley Fool
05:31PM  Mylan Launches Generic Version of Glaxo's Avodart in U.S.
09:34AM  How Does Brexit Impact Healthcare Stocks?
08:45AM  These 3 UK business sectors may be hit hard by Brexit at CNBC
08:03AM  6 ways Brexit could impact Washington business at
07:01AM  Effects of Brexit on Pharmaceuticals and the Biotechnology Industry
Jun-24-16 09:04PM  UW researchers compete for $1M prize from GlaxoSmithKline with device for bladder control, sexual function at
02:41PM  Mylan Unveils Generic Avodart Capsules
01:06PM  Post-Brexit Analysis: Should Investors Buy or Sell Biopharma? at Motley Fool
12:50PM  Post-Brexit opportunities in three British stocks at MarketWatch
Jun-23-16 02:47PM  GlaxoSmithKline Has No Cure for Sideways Action
10:57AM  GAVI alliance offers matched funds for GSK malaria vaccine pilot Reuters
Jun-22-16 08:21AM  Can These Upstarts Knock Gilead Sciences Off Its Perch? at Motley Fool
Jun-21-16 03:03PM  7 Pharmaceutical Stocks With Dividends Yielding More Than 3% at Motley Fool
02:44PM  New Stock Research Reports for June 21, 2016
Jun-20-16 11:42AM  How do I use previous support and resistance levels?
Jun-16-16 10:41AM  3 High-Yield Dividend Stocks You Should Buy as Brexit Fears Swirl
Jun-15-16 03:06PM  3 Beaten-Up Healthcare Stocks: Are They Bargains? at Motley Fool
02:23PM  Perrigo Deal Rumors Are Just Smoke at Bloomberg
12:17PM  What Exactly Are Bio-Electronics? at Bloomberg
09:20AM  Perrigo Rises Further as Takeover Rumor Swirls
Jun-14-16 01:19PM  GlaxoSmithKline (GSK) Stock Lower as Chairman of Vaccines Retires
06:28AM  Glaxos Vaccines Chairman Moncef Slaoui to Retire Next Year at Bloomberg
Jun-13-16 08:30AM  With Brexit Looming, Hedge Funds Weigh In On British Stocks at Insider Monkey
Jun-10-16 09:15AM  ViiV Healthcare Announces FDA Approval to Lower the Weight Limit for dolutegravir in Children and Adolescents Living With HIV PR Newswire
Jun-09-16 11:01AM  Glaxo/J&J Sirukumab Positive in Rheumatoid Arthritis Study
09:44AM  GlaxoSmithKline PLC (ADR) (GSK) To Accelerate Filing For COPD Combo Treatment at Insider Monkey
09:03AM  Better Buy: GlaxoSmithKline vs. Pfizer at Motley Fool
05:01AM  Only One Big Drugmaker Is Working on a Nanobot Cure at Bloomberg
Jun-08-16 05:19PM  Johnson & Johnson (JNJ) And GlaxoSmithKline PLC (ADR) (GSK) Rheumatoid Arthritis Drug Meets Targets In Large Phase 3 Study at Insider Monkey
05:18PM  GlaxoSmithKline PLC (ADR) (GSK) Poised To Overtake Sanofi SA (ADR) (SNY) In This $1.8 Billion Market at Insider Monkey
08:16AM  Viability Statement May Prompt More Candid Disclosure of Risks at The Wall Street Journal
Jun-07-16 04:16PM  Steven Cohen Adds to Stake in Pernix Therapeutics
Jun-06-16 11:10AM  GSK's HIV treatment to be delivered in Botswana in record tender at
09:39AM  U.S. top court rejects GSK bid to throw out racketeering lawsuits Reuters
Jun-03-16 01:41PM  Ionis Pharmaceuticals, Inc. Was Pummeled in May -- Here's Why at Motley Fool
11:41AM  Botswana gets GSK's modern HIV drug in largest ever Africa deal
09:40AM  Glaxo/Innoviva Expedite Closed Triple Combination NDA Filing
07:53AM  In fight for GSK's Advair, generic firms step carefully on price Reuters
07:17AM  Sell Alert: These 5 Stocks Look Toxic Right Now
04:55AM  European, Asian Stock Benchmarks Rise Before Payrolls
Jun-02-16 02:45PM  GlaxoSmithKline And Innoviva Plan To File A NDA For Triple Combination Therapy Benzinga
11:03AM  Alnylam gains a cool $1.5B in market cap on bad news for rival at
11:00AM  Regulatory update on US filing plans for closed triple combination therapy FF/UMEC/VI in patients with COPD PR Newswire
07:00AM  People Will Soon Talk to Web Ads on, Thanks to Watson at The Wall Street Journal
07:00AM  Independence of compliance reviews is questioned in drug firm settlements Reuters
04:00AM  GSK seeks lead in triple lung drug market with 2016 filing plan Reuters
02:31AM  GSK to file 3-in-1 lung drug for U.S. approval this year Reuters
Jun-01-16 07:01PM  Anti-graft group says drugmakers failing to tackle corruption Reuters
06:07PM  Inside Ioniss Key Pipeline Drug IONIS-TTR
12:57PM  Is AstraZenecas Valuation Low Compared to Peers?
08:00AM  Regulus Expands Clinical Trial Collaboration with GSK PR Newswire
May-31-16 09:41AM  Better Buy: Celldex Therapeutics, Inc. vs. Ionis Pharmaceuticals, Inc. at Motley Fool
09:21AM  Ioniss Stock Tanks as GSK Withdraws from Phase 3 Study
May-27-16 02:34PM  Gene therapy helping the blind to see
01:40PM  3 Value Stocks Near 52-Week Lows Worth Buying at Motley Fool
10:45AM  Ionis Down, Glaxo Dumps IONIS-TTRRx Phase III Study Plans
May-26-16 05:00PM  Ionis Hits 3-Year Low As GlaxoSmithKline Drops Big Trial Plans
03:55PM  Why Alnylam Pharmaceuticals, Inc. Competed Higher Today at Motley Fool
01:54PM  Why Ionis Pharmaceuticals Plummeted Today at Motley Fool
12:32PM  [$$] Ionis's Shares Fall After Co-Developer Opts Against Starting Late-Stage Trial at The Wall Street Journal
11:16AM  Why Ionis Pharmaceuticals (IONS) Stock Is Tanking Today
10:47AM  Ionis Pharmaceuticals Inc (IONS) Plunges After GSK Foregos Phase 3 Study of TTRRx at Insider Monkey
May-25-16 11:21AM  Glaxo/Innoviva Report Positive COPD Data on Relvar Ellipta
09:35AM  Could the Worlds Most Effective Quit Smoking Aid be a Low Nicotine Cigarette US Public Health Officials Think So
08:04AM  4 Safe Stocks With Dividend Yields Above 5% at Motley Fool
May-24-16 10:40AM  Why this GSK news is good for workers in Zebulon at
09:36AM  3 Stocks With a Bigger Dividend Than Coca-Cola at Motley Fool
09:04AM  The Best Buys in Biopharma Today at Motley Fool
06:34AM  GSK lung drug succeeds in big UK study, after earlier miss Reuters
05:59AM  Salford Lung Study Results Show COPD Patients Treated With Relvar(R) Ellipta(R) Achieve Superior Reduction in Exacerbations Compared to 'Usual Care' Marketwired
May-23-16 05:53PM  EU lifts suicide warning on Pfizer's smoking-cessation pill
12:02PM  Behind the Worlds Top Drugmakers Approach to Zika Vaccine at Bloomberg
10:02AM  UK drugs watchdog warns it will struggle if Britain leaves EU Reuters
May-20-16 09:35PM  [$$] China Drug Deal Will Slash Prices of Three Top-Selling Treatments at The Wall Street Journal
11:57AM  Drugmakers eye volume growth as China cuts prices by up to 67 pct Reuters
10:41AM  [$$] China Drug Deal Will Slash Prices of Top Treatments at The Wall Street Journal
07:22AM  China slashes GSK, AstraZeneca drug prices in cost-cutting drive Reuters
May-19-16 08:14AM  Glaxo/Innoviva Unveil SUMMIT Study Data on Breo Ellipta
May-18-16 07:07PM  The Reasons behind Mercks Improving Profitability
12:21PM  GSK Presents Efficacy Data for Anoro(R) Ellipta(R) in COPD Patients Who Remained Symptomatic on Tiotropium Marketwired
12:20PM  GSK Present New Data From Breo(R) Ellipta(R) SUMMIT Study in Patients With COPD at ATS Conference Marketwired
May-16-16 11:50AM  3 things you should know about Greater Washingtons bioscience companies at
May-14-16 10:04PM  How Did GSKs HIV Business Perform in 1Q16?
May-11-16 01:05AM  Analyzing the Changes in Novartiss Valuation for 1Q16 Market Realist
May-10-16 02:54PM  Ionis Pharmaceuticals Inc Is Burning Partners' Cash (Thank Goodness There's Lots of It) at Motley Fool
May-09-16 04:07PM  Pfizers 1Q16 Earnings: Products That Saw Sales Drop Market Realist
03:43PM  Here's Why Amarin Corporation's Stock Rallied in April at Motley Fool
May-06-16 11:06AM  How Has GlaxoSmithKlines Valuation Changed in 1Q16? Market Realist
GlaxoSmithKline plc creates, discovers, develops, manufactures, and markets pharmaceutical products, including vaccines, over-the-counter medicines, and health-related consumer products worldwide. The company offers pharmaceutical products in the therapeutic areas, including respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, and emesis, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health areas. The company's wellness products include Panadol and Panadol Cold & Flu for headache, joint pain, fever, and cold symptoms; ENO and Tums that are immediate relief antacids; and Nicorette (US), Nicoderm, NiQuitin CQ, and Nicabate for the treatment of nicotine withdrawal as an aid to smoking reduction and cessation. Its oral health products comprise Sensodyne to treat and prevent dental sensitivity and acid erosion; Polident, Poligrip, and Corega to enhance comfort of fitted dentures and to clean dentures; and Aquafresh for the prevention of caries, gum disease, and bad breath. The company's nutrition products include Horlicks, a nutritional beverages and food; and skin health products comprise Physiogel, a face and body care product for dry, sensitive, and irritated skin, as well as Zovirax and Abreva to treat and prevent the onset of cold sores. GlaxoSmithKline plc has collaboration agreements with Universit de Sherbrooke and Pfizer Inc.; development agreement, and R and D collaboration with Propeller Health; R and D collaboration agreement with Valneva SE; and collaboration and license agreement with Idera pharmaceuticals, Inc. The company was founded in 1935 and is headquartered in Brentford, the United Kingdom.